6LQD image
Deposition Date 2020-01-13
Release Date 2020-03-11
Last Version Date 2024-03-27
Entry Detail
PDB ID:
6LQD
Keywords:
Title:
Structure of Enterovirus 71 in complex with NLD-22
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
3.26 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Capsid protein VP1
Chain IDs:A
Chain Length:297
Number of Molecules:1
Biological Source:Human enterovirus 71
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Capsid protein VP2
Chain IDs:B
Chain Length:254
Number of Molecules:1
Biological Source:Human enterovirus 71
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Capsid protein VP3
Chain IDs:C
Chain Length:242
Number of Molecules:1
Biological Source:Human enterovirus 71
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Capsid protein VP4
Chain IDs:D
Chain Length:69
Number of Molecules:1
Biological Source:Human enterovirus 71
Ligand Molecules
Primary Citation
Design, Synthesis, and Evaluation of Novel Enterovirus 71 Inhibitors as Therapeutic Drug Leads for the Treatment of Human Hand, Foot, and Mouth Disease.
J.Med.Chem. 63 1233 1244 (2020)
PMID: 31939669 DOI: 10.1021/acs.jmedchem.9b01414

Abstact

Human hand, foot, and mouth disease (HFMD) is a serious public health threat with high infection rates in children and infants who reside in Asia and the Pacific regions, and no effective drugs are currently available. Enterovirus 71 (EV71) and coxsackievirus A16 are the major etiological pathogens. Based on an essential hydrophobic pocket on the viral capsid protein VP1, we designed and synthesized a series of small molecular weight compounds as inhibitors of EV71. A potential drug candidate named NLD-22 exhibited excellent antiviral activity (with an EC50 of 5.056 nM and a 100% protection rate for mice at a dose of 20 mg/kg) and low toxicity. NLD-22 had a favorable pharmacokinetic profile. High-resolution cryo-electron microscopy structural analysis confirmed NLD-22 bound to the hydrophobic pocket in VP1 to block viral infection. In general, NLD-22 was indicated to be a promising potential drug candidate for the treatment of HFMD.

Legend

Protein

Chemical

Disease

Primary Citation of related structures